CSF1R and giant cell tumor: DCC-3014 (vimseltinib) is another promising agent that potently inhibits CSF1R (IC50 = 2.2 nM) and is being explored in tenosynovial giant cell tumors in phase 3 clinical trials (NCT05059262), Hodgkin lymphoma (NCT05723055, phase 2), and breast cancer (NCT05491226, phase 2).